RxDoctor Payments Data

William Simpson

Urology · Augusta, GANPI 1508247958

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,483 of the $15,602 with a category attached, or 67.2%. It is spread thinly across 47 manufacturers, the largest accounting for just 20.2%. Reporting peaked in 2023 at $4,765 and has fallen 59.5% since, to $1,932 in 2025.

$15,602in general payments, 2019–2025

Across 321 payments — averaging $48.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Boston Scientific$2K
  • Coloplast$1K
  • Axonics, Inc.$1K
  • Procept Biorobotics Corporation$1K
  • Neotract Inc.$953
  • plus $6K from 41 others

What the payments were for

  • Travel & lodging$2,02213%
  • Food & beverage$10,48367%
  • Education$3,09720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,602 in reported general payments places this provider in the 85th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$523,952
Medicare patients
1,177
Services billed
12,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide43$574,275
OrgovyxRelugolix174$455,717
XtandiEnzalutamide28$396,654
MyrbetriqMirabegron257$150,860
GemtesaVibegron113$65,647
Tamsulosin Hcl1,139$14,434
Finasteride635$8,378
Mirabegron ErMirabegron20$7,208
Trospium Chloride96$5,647
Estradiol92$5,538
Potassium Citrate ErPotassium Citrate53$4,602
Testosterone Cypionate87$2,610
Silodosin20$2,294
Oxybutynin Chloride184$2,038
NitrofurantoinNitrofurantoin Macrocrystal76$1,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$16$574,27543 claims
Astellas Pharma US IncXtandi, Myrbetriq$98$547,514285 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$345$521,364287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 369 urology providers in Georgia.

Other urology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →